Pharmaceutical Report Library l Report Store l Pharma Intelligence

Dengue DNA vaccine

The US Naval Medical Research Center (NMRC) is developing a Vaxfectin (cationic lipid-based adjuvant; Vical)-adjuvanted, tetravalent plasmid DNA vaccine.

January 4, 2018

Find out more

Chronic Heart Failure KOL Interview – US, Midwest

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into patient segmentation, as well as prescribing trends for key marketed brands and late-phase pipeline therapies for chronic heart failure (CHF). Marketed brands discussed include Entresto, Farxiga, Jardiance, Corlanor, and Verquvo, while pipeline therapies highlighted are Furoscix, Invokana, Kerendia, omecamtiv mecarbil, Revascor, and Zynquista.

August 15, 2022

Find out more

Treatment of VTE – US KOL Interview

$599.00

This interview with a US hematologist focuses on the changing dynamics with the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.

November 2, 2015

Find out more

Germany, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

$1,995.00

This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries

November 1, 2012

Find out more

Leading Players in the CMO Market

$5,000.00

he following companies are the 10 largest small-molecule contract manufacturing organizations (CMOs) by revenue. While many of the firms also contain biologics businesses, where possible only the relevant small-molecule revenues have been counted.

November 3, 2016

Find out more

Oral Vidaza

Oral Vidaza is an orally available formulation of Vidaza (azacitidine; Celgene/Nippon Shinyaku), a small molecule cytidine nucleoside analog that exerts its anti-cancer activity through direct cytotoxicity as well as through DNA hypomethylation.

July 6, 2017

Find out more

Renal Cell Carcinoma KOL Interview – US, Southeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for renal cell carcinoma. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Cabometyx, Keytruda, Inlyta, Lenvima, and Tecentriq.

May 13, 2020

Find out more

Bax 817

BAX 817 is an rfVIIa therapy in development by Baxalta for patients with hemophilia A or B with inhibitors. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X…

March 14, 2016

Find out more

Cinqair

Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, which are inflammatory white blood cells implicated in a number of allergic diseases, including asthma.

February 16, 2018

Find out more

Macitenan for Pulmonary Arterial Hypertension

$89.00

Macitentan is a novel dual endothelin receptor antagonist (ERA)

showing sustained receptor occupancy

March 1, 2014

Find out more

Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy and CD20-directed bispecific antibodies.

April 21, 2022

Find out more

Orthobiologics for Musculoskeletal Soft Tissue Replacement and Regeneration – 2021

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration. Geographic markets covered by this analysis comprise the US, Japan, five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW), which includes all other countries.

November 2, 2021

Find out more

Xadago

Xadago (safinamide; Newron Pharmaceuticals/US WorldMeds/Zambon/Meiji Seika Pharma) has a novel dual mechanism of action, based on the enhancement of the dopaminergic function through the reversible inhibition of monoamine oxidase B (MAO-B) and inhibition of excessive glutamate release by blocking the activity of the voltage-dependent sodium channels.

June 21, 2018

Find out more

capivasertib

Capivasertib (AstraZeneca) is an orally active, highly selective Akt inhibitor that preferentially targets Akt isoforms 1–3. Akt is a key enzyme in the PI3K/Akt/mTOR tumor cell survival pathway and is dysregulated in a number of malignancies through loss of tumor suppressor phosphatase and tensin homolog (PTEN), acquisition of activating mutations in phosphatidylinositol-4,5-bisphosphate 3- kinase catalytic subunit alpha (PIK3CA) or AKT1, as well as amplification of PI3K.

February 26, 2020

Find out more

Disease Analysis: Type 2 Diabetes

Diabetes mellitus is a group of metabolic disorders which are characterized by hyperglycemia (elevated blood glucose levels) due to insufficient insulin secretion, which in type 2 diabetes occurs in the setting of insulin insensitivity.

September 14, 2022

Find out more

Spain, Surgical Procedure Volumes

$4,850.00

This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union country of Spain.

November 1, 2013

Find out more

Epogen

Epogen is an ESA administered by intravenous or subcutaneous injection, and is indicated for the treatment of CIA.

January 11, 2018

Find out more

Triple-Negative Breast Cancer KOL Interview – US

$599.00

A US-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

October 3, 2019

Find out more

Thalomid

Thalomid contains thalidomide, a glutamic acid derivative that possesses immunomodulatory, antiinflammatory,
and anti-angiogenic properties.

August 9, 2018

Find out more

Market Spotlight: Hepatitis B

$1,318.00

This Market Spotlight report covers the Hepatitis B market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

August 5, 2022

Find out more

2019 Post-ADA Report

$2,995.00

July 22, 2019

Find out more

Effient

An oral antiplatelet agent, Effient is a pro-drug which is converted to its active metabolite after
metabolism by cytochrome P450 enzymes.

April 14, 2016

Find out more

U.S. Surgical Procedure Volumes

$4,750.00

This report presents the most common surgical procedures performed in the United States (U.S.) as well as an overview of the etiology and epidemiology of selected diseases/disorders, prevailing surgical approaches/techniques, and evolving procedural utilization trends.

November 1, 2015

Find out more

Schizophrenia and Bipolar Disorder KOL Interview – US, East Coast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Find out more

Market Spotlight: Opioid-Induced Constipation

$1,318.00

This Market Spotlight report covers the Opioid-Induced Constipation (OIC) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and epidemiology data, as well as presenting drug-specific revenue forecasts.

October 26, 2022

Find out more

Nexavar

Nexavar (sorafenib; Bayer/Amgen) is a small molecule inhibitor that is currently the only targeted treatment available for first-line hepatocellular carcinoma patients.

September 9, 2019

Find out more

Pulmonary Hypertension KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Adempas, Letairis, Opsumit, Orenitram, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.

July 21, 2022

Find out more

FluMist QIV

FluMist QIV (AstraZeneca/Daiichi Sankyo) is a quadrivalent live-attenuated influenza vaccine containing antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.

January 10, 2019

Find out more

RSV preF vaccine

Pfizer’s RSV preF vaccine is based on the prefusion form of the RSV fusion protein, aided by the discovery of the crystal structure of key viral proteins by the National Institutes of Health.

October 5, 2018

Find out more

Briviacti

Briviact (brivaracetam; UCB) is a follow-on product to Keppra (levetiracetam; UCB/Otsuka), acting as an anticonvulsant by binding to the synaptic vesicle glycoprotein 2A (SV2A), directly causing…

June 7, 2016

Find out more

Acute Myeloid Leukemia (AML) KOL Interview – US, East Coast

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

April 1, 2020

Find out more

SAGE-217

SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) is a novel, next-generation positive allosteric modulator that selectively binds synaptic and extrasynaptic gamma-aminobutyric acid-A (GABA-A) receptors and shares similar pharmacology properties to brexanolone.

March 29, 2019

Find out more

Afrezza

Afrezza (inhaled human insulin; Sanofi) is a drug-device combination product consisting of an ultra-rapid-acting human insulin for oral inhalation, approved for use in the US for the treatment of type 1 and type 2 diabetes.

November 7, 2017

Find out more

Herceptin

Herceptin is a humanized MAb targeting the HER2 receptor, a member of the human epidermal

growth factor receptor family.

March 22, 2016

Find out more

Sutent

Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and FLT3.

March 6, 2019

Find out more

Adcirca

Launching after Revatio, Adcirca became the second-to-market PDE5 inhibitor upon its approval in major markets in 2009. Inhibiting the PDE5 enzyme enhances the effect of the endogenous vasodilator, nitric oxide (NO).

October 29, 2018

Find out more

PD-1/L1 Immunotherapies: Historical Sales and Market Trend Analysis Report

$7,500.00

Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) has outpaced Merck’s Keytruda (pembrolizumab) primarily
in non-small cell lung cancer (NSCLC) because of its early approval in squamous NSCLC, updated National
Comprehensive Cancer Network (NCCN) guidelines in 2015,

December 22, 2016

Find out more

Avonex

Avonex is a biological therapy derived from the interferon family, and Biogen’s leading drug for treating relapsing-remitting multiple sclerosis (RRMS).

November 24, 2017

Find out more

Zykadia

Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK).

August 30, 2018

Find out more

US Pricing and Reimbursement

$2,995.00

Historically, few pricing controls have been implemented in the US; however, there is greater pressure to implement controls to help contain costs associated with the expansion of public healthcare provision.

November 2, 2016

Find out more

Colorectal Cancer KOL Interview – UK

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.

May 23, 2022

Find out more

U.S. Markets for Orthopedic Biologic and Tissue Engineered Products

$4,750.00

Tissue engineering, or regenerative medicine, represents a promising therapeutic possibility for the treatment of aggressive and deadly diseases.

September 22, 2016

Find out more

Ovarian Cancer KOL Interview – US, East Coast

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.

April 1, 2020

Find out more

India Regulatory Issues

$2,995.00

The drug approval process in India is not complex, although poor patent protection and government policies favoring generic companies make multinational companies (MNCs) wary of launching new drugs in the country.

November 1, 2016

Find out more

Synribo

Synribo (omacetaxine mepesuccinate; Teva/Hospira) is a subcutaneously formulated, semisynthetic form of homoharringtonine, a naturally occurring alkaloid. In vitro studies show that Synribo binds to the ribosomal A-site cleft, inhibiting synthesis of a number of key oncoproteins.

December 7, 2017

Find out more

Report library

Dengue DNA vaccine

Chronic Heart Failure KOL Interview – US, Midwest

Treatment of VTE – US KOL Interview

Germany, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

Leading Players in the CMO Market

Oral Vidaza

Renal Cell Carcinoma KOL Interview – US, Southeast

Bax 817

Cinqair

Macitenan for Pulmonary Arterial Hypertension

Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

Orthobiologics for Musculoskeletal Soft Tissue Replacement and Regeneration – 2021

Xadago

capivasertib

Disease Analysis: Type 2 Diabetes

Spain, Surgical Procedure Volumes

Epogen

Triple-Negative Breast Cancer KOL Interview – US

Thalomid

Market Spotlight: Hepatitis B

2019 Post-ADA Report

Effient

U.S. Surgical Procedure Volumes

Schizophrenia and Bipolar Disorder KOL Interview – US, East Coast

Market Spotlight: Opioid-Induced Constipation

Nexavar

Pulmonary Hypertension KOL Interview – US #1

FluMist QIV

RSV preF vaccine

Briviacti

Acute Myeloid Leukemia (AML) KOL Interview – US, East Coast

SAGE-217

Afrezza

Herceptin

Sutent

Adcirca

PD-1/L1 Immunotherapies: Historical Sales and Market Trend Analysis Report

Avonex

Zykadia

US Pricing and Reimbursement

Colorectal Cancer KOL Interview – UK

U.S. Markets for Orthopedic Biologic and Tissue Engineered Products

Ovarian Cancer KOL Interview – US, East Coast

India Regulatory Issues

Synribo